Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 137-143

  Steeghs, Neeltje ^a   Gelderblom, Hans ^a   Wessels, Judith ^a   Eskens, Ferry A L M ^b   De Bont, Natasja ^c   Nortier, Johan W R ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Bayer Pharmaceuticals Corporation   (Netherlands)

Author keywords

Angiogenesis; Cancer; Pharmacogenetics; Telatinib; VEGFR

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER C1; BREAST CANCER RESISTANCE PROTEIN; TELATINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADRENAL CANCER; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EXPOSURE; ESOPHAGUS CANCER; FEMALE; GENE FREQUENCY; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC LINKAGE; GENETIC SELECTION; HAPLOTYPE; HUMAN; HYPERTENSION; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 79151468933     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9347-0     Document Type: Article

References (21)

1. JT Auman HL McLeod 2008 Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity Drug Metab Rev 40 303 315 1:CAS:528:DC%2BD1cXnsVyqsLw%3D 10.1080/03602530801952427 18464047
2. JJ Swen TW Huizinga H Gelderblom EG de Vries WJ Assendelft J Kirchheiner HJ Guchelaar 2007 Translating pharmacogenomics: challenges on the road to the clinic PLoS Med 4 e209 10.1371/journal.pmed.0040209 17696640
3. Investigator's brochure BAY 57-9352 (Telatinib) (2007) Bayer Healthcare. Martville, NJ, USA
4. FA Eskens N Steeghs J Verweij JL Bloem O Christensen L van Doorn J Ouwerkerk MJ de Jonge JW Nortier J Kraetzschmar P Rajagopalan H Gelderblom 2009 Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors J Clin Oncol 27 4169 4176 1:CAS:528:DC%2BD1MXhtF2jtLrK 10.1200/JCO.2008.18.8193 19636022
5. D Strumberg JW Clark A Awada MJ Moore H Richly A Hendlisz HW Hirte JP Eder HJ Lenz B Schwartz 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 1:CAS:528: DC%2BD2sXmtlSitrs%3D 10.1634/theoncologist.12-4-426 17470685
6. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 1:CAS:528: DC%2BD28Xot1ChtQ%3D%3D 10.1200/JCO.2005.02.2194 16314617
7. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij GM Van AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
8. S Purcell B Neale K Todd-Brown L Thomas MA Ferreira D Bender J Maller P Sklar PI de Bakker MJ Daly PC Sham 2007 PLINK: a tool set for whole-genome association and population-based linkage analyses Am J Hum Genet 81 559 575 1:CAS:528:DC%2BD2sXhtVSqurrL 10.1086/519795 17701901
9. N Steeghs H Gelderblom JO Roodt O Christensen P Rajagopalan M Hovens H Putter TJ Rabelink E de Koning 2008 Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor Clin Cancer Res 14 3470 3476 1:CAS:528:DC%2BD1cXmslygtr8%3D 10.1158/1078-0432.CCR-07-5050 18519779
10. RB Diasio 2001 Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology Oncology (Williston Park) 15 21 26 1:STN:280: DC%2BD3M3isFemug%3D%3D
11. SA Ridge J Sludden X Wei A Sapone O Brown S Hardy P Canney P Fernandez-Salguero FJ Gonzalez J Cassidy HL McLeod 1998 Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer Br J Cancer 77 497 500 1:CAS:528:DyaK1cXhtV2huro%3D 9472650
12. L Iyer S Das L Janisch M Wen J Ramirez T Karrison GF Fleming EE Vokes RL Schilsky MJ Ratain 2002 UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 43 47 1:CAS:528:DC%2BD38Xitl2ju7k%3D 10.1038/sj.tpj.6500072 11990381
13. F Innocenti SD Undevia J Ramirez S Mani RL Schilsky NJ Vogelzang M Prado MJ Ratain 2004 A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital Clin Pharmacol Ther 76 490 502 1:CAS:528:DC%2BD2cXpslWntL0%3D 10.1016/j.clpt.2004.07.016 15536463
14. DM Kweekel H Gelderblom Van der ST NF Antonini CJ Punt HJ Guchelaar 2008 UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study Br J Cancer 99 275 282 1:CAS:528:DC%2BD1cXosFWnsb0%3D 10.1038/sj.bjc.6604461 18594531
15. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discov Today 12 1054 1060 1:CAS:528:DC%2BD2sXhsVSmurnL 10.1016/j.drudis.2007.10.016 18061885
16. G Pasqualetti R Danesi TM Del G Bocci 2007 Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy Pharmacogenomics 8 49 66 1:CAS:528:DC%2BD2sXhvFylt7s%3D 10.2217/14622416.8.1.49 17187509
17. H Kariyazono T Ohno V Khajoee K Ihara K Kusuhara N Kinukawa Y Mizuno T Hara 2004 Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease Pediatr Res 56 953 959 1:CAS:528:DC%2BD2cXpsl2jtrc%3D 10.1203/01.PDR.0000145280. 26284.B9 15470196
18. HW Park JE Lee ES Shin JY Lee JW Bahn HB Oh SY Oh SH Cho HB Moon KU Min JA Elias YY Kim YK Kim 2006 Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population J Allergy Clin Immunol 117 774 779 1:CAS:528:DC%2BD28Xjslels7g%3D 10.1016/j.jaci.2005.12.1328 16630933
19. BP Schneider M Wang M Radovich GW Sledge S Badve A Thor DA Flockhart B Hancock N Davidson J Gralow M Dickler EA Perez M Cobleigh T Shenkier S Edgerton KD Miller 2008 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 4672 4678 1:CAS:528:DC%2BD1cXht1KqtLfE 10.1200/JCO.2008.16.1612 18824714
20. MV Relling JM Hoffman 2007 Should pharmacogenomic studies be required for new drug approval? Clin Pharmacol Ther 81 425 428 1:STN:280: DC%2BD2s7jvFyksg%3D%3D 10.1038/sj.clpt.6100097 17339872
21. AD Roses 2008 Pharmacogenetics in drug discovery and development: a translational perspective Nat Rev Drug Discov 7 807 817 1:CAS:528: DC%2BD1cXhtFOlu7jN 10.1038/nrd2593 18806753